Join the VISIONaerieS™
Inspiration, imagination, and innovation. We share this passion for finding new approaches to protecting vision. United by great science, deep clinical insight, and a singular focus on your ophthalmic needs, we see the possibilities ahead and invite you to join us in creating the future of eye care.
We are a publicly traded (NASDAQ: AERI), ophthalmic pharmaceutical company focused on the discovery, development and commercialisation of first-in-class therapies for the treatment of patients with open-angle glaucoma and other diseases of the eye.
Glaucoma is one of the largest segments in the global ophthalmic market, exceeding $5b in 2016 in the United States, Europe and Japan. Glaucoma is a progressive disease in which elevated levels of intraocular pressure, or IOP, are associated with damage to the optic nerve, resulting in irreversible vision loss and potentially blindness. Additionally, glaucoma is a highly individualised disease and there is no direct correlation of the level of IOP at diagnosis with damage to the optic nerve.
Our first product, Rhopressa® (netarsudil ophthalmic solution) 0.02%, was approved by the United States Food & Drug Administration (FDA) in December 2017 for the lowering of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension. Our second product, Roclatan™ (netarsudil/latanoprost ophthalmic solution) 0.02%/0.005%, is a fixed dose combination of Rhopressa® and latanoprost, a widely prescribed prostaglandin analogue (PGA). We expect to file our NDA for Roclatan™ in the second quarter of 2018.
If approved, we believe Roclatan™ has the potential to be the most efficacious therapy for lowering of elevated IOP in the marketplace.